Jasmine H Francis1,2, Jonathan Kim3, Amy Lin4, Robert Folberg5, Saipriya Iyer1, David H Abramson1,2. 1. Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY. 2. Department of Ophthalmology, Weill Cornell Medical College, New York, NY. 3. Department of Ophthalmology, University of Southern California, Los Angeles, CA, USA. 4. University of Illinois Hospital and Health Sciences System, Chicago, IL, USA. 5. Oakland University William Beaumont School of Medicine, Rochester, MI, USA.
Abstract
PURPOSE: Typically treatment of large melanomas (by Collaborative Ocular Melanoma Study criteria) is restricted to enucleation, due to size constraints for plaque brachytherapy. Because primary and metastatic uveal melanoma cells are inhibited by bevacizumab (an anti-vascular endothelial growth factor), this prospective study evaluated the impact of intravitreal bevacizumab on large uveal melanomas that were destined for enucleation. Size reduction by bevacizumab would potentially salvage these eyes by making them eligible for treatment with plaque brachytherapy. PROCEDURES: Two patients with large uveal melanoma were each treated with one intravitreous injection of bevacizumab (1.25 mg/0.05 mL). RESULTS: Both tumors displayed paradoxical growth 1 week following the injection, with confirmed growth 1 week later (increase from baseline of 1.1 mm in one eye and 3.1 mm in the other eye). Both eyes were enucleated and monosomy 3 and vasculogenic mimicry patterns were identified in both tumors. At 9 years follow-up, both patients were alive and metastasis free. CONCLUSION: These patients demonstrate that neoadjuvant intravitreous bevacizumab does not decrease the size of large uveal melanomas and may, in fact, result in their paradoxical growth. This observation supports a cautious approach in the use of intravitreous bevacizumab for uveal melanoma, particularly in the neoadjuvant setting.
PURPOSE: Typically treatment of large melanomas (by Collaborative Ocular Melanoma Study criteria) is restricted to enucleation, due to size constraints for plaque brachytherapy. Because primary and metastatic uveal melanoma cells are inhibited by bevacizumab (an anti-vascular endothelial growth factor), this prospective study evaluated the impact of intravitreal bevacizumab on large uveal melanomas that were destined for enucleation. Size reduction by bevacizumab would potentially salvage these eyes by making them eligible for treatment with plaque brachytherapy. PROCEDURES: Two patients with large uveal melanoma were each treated with one intravitreous injection of bevacizumab (1.25 mg/0.05 mL). RESULTS: Both tumors displayed paradoxical growth 1 week following the injection, with confirmed growth 1 week later (increase from baseline of 1.1 mm in one eye and 3.1 mm in the other eye). Both eyes were enucleated and monosomy 3 and vasculogenic mimicry patterns were identified in both tumors. At 9 years follow-up, both patients were alive and metastasis free. CONCLUSION: These patients demonstrate that neoadjuvant intravitreous bevacizumab does not decrease the size of large uveal melanomas and may, in fact, result in their paradoxical growth. This observation supports a cautious approach in the use of intravitreous bevacizumab for uveal melanoma, particularly in the neoadjuvant setting.
Authors: J P Yang; Y D Liao; D M Mai; P Xie; Y Y Qiang; L S Zheng; M Y Wang; Y Mei; D F Meng; L Xu; L Cao; Q Yang; X X Yang; W B Wang; L X Peng; B J Huang; C N Qian Journal: Angiogenesis Date: 2016-02-22 Impact factor: 9.596
Authors: A J Maniotis; R Folberg; A Hess; E A Seftor; L M Gardner; J Pe'er; J M Trent; P S Meltzer; M J Hendrix Journal: Am J Pathol Date: 1999-09 Impact factor: 4.307
Authors: Es Rennel; E Waine; H Guan; Y Schüler; W Leenders; J Woolard; M Sugiono; D Gillatt; Es Kleinerman; Do Bates; Sj Harper Journal: Br J Cancer Date: 2008-03-18 Impact factor: 7.640
Authors: David O Bates; Paul J Catalano; Kirsty E Symonds; Alex H R Varey; Pramila Ramani; Peter J O'Dwyer; Bruce J Giantonio; Neal J Meropol; Al Bowen Benson; Steven J Harper Journal: Clin Cancer Res Date: 2012-10-25 Impact factor: 12.531
Authors: Klára Fodor; Éva Sipos; Nikoletta Dobos; János Nagy; Zita Steiber; Gábor Méhes; Kata Dull; Lóránt Székvölgyi; Andrew V Schally; Gábor Halmos Journal: Life (Basel) Date: 2020-11-25
Authors: Lia Walcher; Clara Budde; Arina Böhm; Peter S Reinach; Priyavathi Dhandapani; Nina Ljubojevic; Markus W Schweiger; Henriette von der Waydbrink; Ilka Reimers; Josef Köhrle; Stefan Mergler Journal: Front Pharmacol Date: 2018-11-13 Impact factor: 5.810